Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bryan Barnes

Neurological Surgery Athens, GA Medical Doctor

NPI 1548281363 CMS profile 251160

2142 W Broad St, Bldg 100, Ste 200, Suite 200, Athens, GA 30606

Open in the dashboard

General payments

$133,673

31 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bryan Barnes of Athens, GA is reported in the CMS Open Payments database as having received $133,673 across 31 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,264 3
2024 General $500 1
2023 General $270 2
2022 General $7,547 4
2021 General $22,023 5
2020 General $24,323 7
2019 General $77,746 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bryan Barnes
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Bryan Barnes were reported at $1,264. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Bryan Barnes Neurological Surgery median Middle half National median
2019 $77,746 $582 $138–$3,006 $163
2020 $24,323 $294 $76–$2,174 $114
2021 $22,023 $387 $105–$2,432 $132
2022 $7,547 $542 $139–$2,989 $149
2023 $270 $534 $145–$2,697 $160
2024 $500 $574 $155–$3,046 $164
2025 $1,264 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Life Spine, Inc. $118,819 14 payments
  2. Choice Spine, LLC $14,606 10 payments
  3. Zimmer Biomet Holdings, Inc. $189 3 payments
  4. AbbVie, Inc. $46 3 payments
  5. Boston Scientific Corporation $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $115,086 7 payments
  2. Consulting Fee $16,250 9 payments
  3. Travel and Lodging $1,784 2 payments
  4. Food and Beverage $364 10 payments
  5. Education $189 3 payments
Products named General payments · program years 2019–2025
  1. ProLift Spinal Surgery $23,134 3 payments
  2. ProLift Spinal Surgery $16,951 2 payments
  3. TigerShark X $9,000 6 payments
  4. THUNDERBOLT MINIMALLY INVASIVE PEDICLE SCREW SYSTEMS Spinal Implant $5,034 2 payments
  5. Cervical MIS $1,000 1 payment
  6. Thunderbolt Minimally Invasive Pedicle Screw Systems Spinal Implant $500 1 payment
  7. Biomet SpinalPak $189 3 payments
  8. Stratofuse $72 1 payment
  9. Blackhawk Ti $72 1 payment
  10. Boomerang $72 1 payment
  11. Other $216 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

778

Median for Neurosurgery: 83

Drug cost

$7,256

Median for Neurosurgery: $872

Branded share of claims

14.5%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 282 $1,616
Lidocaine Generic 13 $1,485
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 86 $1,236
Methocarbamol Generic 126 $916
Gabapentin Generic 53 $578
Cyclobenzaprine Hcl Generic 74 $452
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 27 $283
Methylprednisolone Generic 40 $268
Tizanidine Hcl Generic 27 $213
Pregabalin Generic 12 $102

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 84 billing codes

Paid by Medicare

$443,037

Medicare's payments for the services billed

Medicare patients

404

Average age 74

Services billed

1,385

212 women, 192 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 31%
Diabetes 29%
Chronic kidney disease 29%
Ischemic heart disease 28%
Atrial fibrillation 22%
Osteoporosis 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

31 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record